CBD was administered orally in the form of oral gelatin capsules at doses ranging from 600 to 1,000 mg / day and the effects were compared with placebo and active control. Evaluated the effects of CBD (600 mg / day for 6 weeks) as an adjunct treatment in patients with chronic schizophrenia over a 6 week period. No significant differences were observed between the placebo group and CBD in cognitive function and psychotic symptoms . Includes a small group of patients with acute schizophrenia who received 200 to 800 mg / day or amisulpride for 4 weeks, a potent antipsychotic. CBD was as effective as amisulpride in improving psychotic symptoms and was associated with clear tolerability and safety compared to amisulpride .
Regarding the efficacy of CBD in the treatment of schizophrenia and / or substance abuse disorders, he noted large differences in the population, doses and administration of the study . In the current review, two main results were considered for patients with schizophrenia, psychotic symptoms and cognitive functioning. CBD had a positive effect on psychotic symptoms, especially in patients with acute psychotics, while it had little or no effect in patients with chronic schizophrenia treated with antipsychotics. The possibility that greater effects for patients may be observed in the early stages of the disease has been suggested .
Naftali T, Mechulam R, Marii A, Gabay G, Stein A, Bronshtain M, Laish I. Et al. the low dose of cannabidiol is safe but ineffective in the treatment of Crohn’s disease, cbd oil by mail a randomized controlled study. This systematic review evaluated the dosing schedules, the effects and security concerns associated with the use of CBD.
Cannabidiol may decrease the rate at which the body breaks down brivaracetam. Carbamazepine Carbamazepine is changed and broken by the body. Cannabidiol may reduce the rate at which the body breaks down carbamazepine. This can increase carbamazepine levels in the body and increase side effects. Cannabidiol may decrease the rate at which the liver breaks down clobazam.
Taking into account data from in vitro and in vivo studies, cannabidiol appears to be a promising candidate for the treatment of somatic and psychiatric disorders. The purpose of this assessment was to collect dose reports, dosing schedules, efficacy and safety from the use of CBD in adults from clinical studies. The PubMed, Embase and Cochrane library systematically searched for articles published in English between January 1, 2000 and October 25, 2019.
Cannabidiol may decrease the rate at which the body breaks down tacrolimus. Cannabidiol can affect how quickly the body breaks down tamoxifen. Cannabidiol can reduce how quickly the body breaks down topiramate. This can increase the topiramate levels in the body by a small amount. The use of cannabidiol with valproic acid can increase the risk of liver damage.
Without sufficient high-quality evidence in human studies, we cannot determine effective doses and since CBD is currently mainly available as an unregulated supplement, it is difficult to know exactly what you are getting. If you decide to try CBD, contact your doctor for a reason other than to make sure it doesn’t affect other medications you are taking. CBD has the potential to handle many other products, including over-the-counter medicines, herbal products and prescription medicines. Some medicines should never be taken with CBD; The use of other medicines may need to be adjusted or reduced to avoid serious problems.